---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-003143"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2025-03-17T23:59:59+00:00"
generated_at: "2026-05-24T14:55:19.809354+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Protalix increases ATM equity offering capacity by $20M for general corporate purposes

## Summary
- Amendment with H.C. Wainwright increases ATM offering capacity by $20M in aggregate gross sales price.
- Net proceeds will be used for general corporate purposes, including working capital and clinical trials.
- Prospectus supplement filed to register additional shares under existing shelf registration statement.
- No shares were previously available for sale under the existing Sales Agreement.

## SEC filing metadata
- accession: 0001558370-25-003143
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2025-03-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000155837025003143/0001558370-25-003143-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000155837025003143/plx-20250317x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-003143
- JSON: https://secwatch.observer/filing/0001558370-25-003143.json
- Plain text: https://secwatch.observer/filing/0001558370-25-003143.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.